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Unblinded outcome assessment can lead to biased estimates of treatment effect in rando-
mised trials. We reviewed published trials to assess how often blinded assessment is used,
and whether its use varies according to the type of outcome or assessor.
Design and setting
A review of parallel group, individually randomised phase III trials published in four general
medical journals (BMJ, Journal of the American Medical Association, The Lancet, and New
England Journal of Medicine) in 2010.
Main outcomemeasures
Whether assessment of the primary outcome was blinded, and whether this differed accord-
ing to outcome or assessor type.
Results
We identified 258 eligible trials. Of these, 106 (41%) were reported as double-blind, and 152
(59%) as partially or fully open-label (that is, they included some groups who were
unblinded, such as patients, those delivering the intervention, or those in charge of medical
care). Of the 152 open trials, 125 required outcome assessment. Of these 125 trials, only
26% stated that outcome assessment was blinded; 51% gave no information on whether
assessment was blinded or not. Furthermore, 18% of trials did not state who performed the
assessment. The choice of outcome type (e.g. instrument measured, rated, or naturally
occurring event) did not appear to influence whether blinded assessment was performed
(range 24-32% for the most common outcome types). However, the choice of outcome
assessor did influence blinding; independent assessors were blinded much more frequently
(71%) than participant (5%) or physician (24%) assessors. Despite this, open trials did not
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use independent assessors any more frequently than double-blind trials (17% vs. 18%
respectively).
Conclusions
Blinding of outcome assessors is infrequently used and poorly reported. Increased use of
independent assessors could increase the frequency of blinded assessment.
Introduction
A key component of randomised controlled trials is the assessment of patient outcomes, which
involves assigning an outcome value to each trial participant. It is often recommended that out-
come assessors are blinded to treatment allocation, as failure to do so can lead to systematic dif-
ferences between treatment groups, resulting in biased estimates of the treatment effect [1–10].
Previous reviews have found that unblinded outcome assessment can lead to estimates of treat-
ment effect that are exaggerated between 27% and 68%, depending on outcome type [1–3].
Despite the wide body of evidence supporting blinded outcome assessment to prevent bias
in estimated treatment effects, it is still unclear how often it is used in practice. Most previous
reviews have largely focused on specific disease areas [9, 11] or specific subsets of trials [12,
13], such as those that used at least some element of blinding. We therefore undertook a review
of trials published in general medical journals to assess how often blinded outcome assessment
was used, with a focus on trials that were not fully blinded.
Methods
We included parallel group, individually randomized, controlled trials which were published in
one of four major medical journals in 2010 (BMJ, Journal of the American Medical Association,
The Lancet, and New England Journal of Medicine). Pilot and phase I or II trials, as well as arti-
cles that reported only secondary analyses were excluded. Trials were identified from the elec-
tronic table of contents for each journal. One reviewer determined whether trials met the
eligibility criteria for all trials identified; a second reviewer assessed this for a subset of trials
(n = 61), and agreement was 100%. Full details of the search strategy and inclusion/exclusion
criteria have been published elsewhere [14]. We chose to review phase III articles from high
impact general medical journals to focus on trials that were likely to have the greatest impact
on patient care.
We extracted data onto a standardised form, and all trials were independently assessed by
two different reviewers. Disagreements between reviewers were resolved by discussion, or by a
third reviewer if necessary. For each trial, information was extracted on the blinding status of
the trial, how the primary outcome was recorded, who assessed the primary outcome, and
whether the assessor was blinded to treatment allocation. We identified the primary outcome
as follows: (a) if only one outcome was identified as the primary, we used this; (b) if no out-
comes were identified as the primary, we used the first outcome presented in the results section
of the abstract; and (c) if multiple outcomes were identified as primary, we used the first of
these outcomes presented in the results section of the abstract.
We classified trials as either being reported as double-blind or partially (or fully) open-label
(referred to as ‘open’). We categorised trials as being ‘reported as double-blind’ if this was
explicitly stated in the article, if the article stated that everyone involved in the study was
blinded, or if they used a placebo or sham treatment that was described as being identical to
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the intervention in terms of appearance. We categorised trials as being ‘reported as open’ when
it was explicitly stated, or implied through the description of the interventions, that at least
some trial personnel were not blinded to treatment allocation. This included (but was not lim-
ited to) participants, those administering the intervention, those providing medical care apart
from the intervention, and those assessing outcomes.
Definition of outcome and assessor types
Outcomes were grouped into the following categories: instrument measured, rated, naturally
occurring event, action-based event, all-cause mortality, other, or a composite of multiple
outcome types. Full details are shown in Table 1. We defined instrument measured, rated, nat-
urally occurring and action-based events as requiring assessment. We defined all-cause mortal-
ity as not requiring assessment. For outcomes defined as ‘other’, we decided on a case by case
basis whether they required assessment.
Assessors were classified as follows: participant, carer or physician, and independent asses-
sors. Carers or physicians were people who provided some aspect of medical care, or helped to
deliver the intervention. Independent assessors were those who, apart from assessing the out-
come, had no other involvement with participants. For each outcome, we defined the assessor
as the person who primarily recorded or judged the outcome. For example, for rated outcomes,
the assessor was the person who made the rating; for naturally occurring events, the assessor
was the person who decided whether the event had occurred or not; for action-based events,
the assessor was the person who made the decision which led to the event; and for instrument
measured outcomes, the assessor was the person who operated the instrument which directly
provided outcome results.
We defined outcome assessment as being blinded if the article either (a) stated that blinded
outcome assessment had been performed; or (b) identified who assessed the outcome, and
identified this person as being blinded. We defined outcome assessment as being unblinded if
the article either (i) stated that the assessment was not blinded; or (ii) identified the person
who performed the assessment, and identified this person as being unblinded. When the
assessment did not fall into either category, we listed it as unclear.
Results
Trial characteristics
In total, 258 trials met our eligibility criteria and were included in our review. General trial
characteristics are shown in Table 2. Overall, 106 trials (41%) were reported as double-blinded,
and 152 (59%) as partially or fully open-label (hereafter referred to as ‘open’). Of the trials
reported as double blind, the majority used a pharmacological intervention (n = 97/106, 92%).
In comparison, the majority of open trials used a non-pharmacological intervention (n = 100/
152, 66%). Open trials often had poor descriptions of who was blinded; 61% did not state
whether participants were blinded, and 68% did not state whether carers or physicians were
blinded.
Use of blinded outcome assessment
Results are shown in Table 3 and in Fig 1. In total, 27 open trials used an outcome that did not
require formal assessment (26 all-cause mortality, 1 other). Among the 125 open trials where
outcome assessment was required, only 33 (26%) stated that they used blinded outcome assess-
ment; 64 (51%) did not report whether assessment was blinded or unblinded. Furthermore, 22
trials (18%) did not state who performed the assessment.
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Blinding status by outcome or assessor type
Results are shown in Tables 4 and 5. In open trials, the choice of outcome type appeared to
have little effect on whether blinded outcome assessment was used. The proportion of trials
using blinded assessment for instrument measured outcomes, rated outcomes, naturally occur-
ring events, or composite outcomes varied between 24–32%. The one exception was action-
based events, where only one open trial (11%) used blinded assessment.
Conversely, the rates of blinded outcome assessment varied substantially depending on the
choice of assessor. Only one open trial (5%) which used patient assessment and 6 trials (24%)
which used a carer or physician assessment used blinded assessment; in comparison, 15 trials
(71%) using an independent assessor used blinded assessment.
There did not appear to be any difference between double-blind and open trials in the use of
independent assessors (double-blind 18% vs. open 17%). However, there may have been differ-
ences across specific outcomes; for example, open trials used independent assessment for 43%
of naturally occurring events, compared with 27% of double-blind trials.
Discussion
There is substantial evidence to suggest that unblinded outcome assessment can lead to biased
estimates of treatment effect. It is therefore recommended that blinded outcome assessment is
used to avoid this source of bias. Our review identified 125 partially or fully open-label trials
which required outcome assessment. Despite recommended practice, only 26% of trials used
blinded assessment. The true figure may be higher, but is difficult to ascertain for certain due
to poor reporting; over half of trials did not provide any information on whether outcome
Table 1. Definition of outcome types.
Outcome type Deﬁnition Assessor Examples
Instrument
measured
Measurements that are directly observed from
an instrument, without requiring interpretation of
the output by an assessor.
The person who operated the
instrument which directly
provided outcome results.
The patient’s blood pressure at 6 months; the
assessor is the person who takes the patient’s
blood pressure.
Rated A score or summary measure that is assigned to
some aspect of the patient’s wellbeing.
The person who makes the
rating.
The patient completes a visual analogue scale
from 0-100mm indicating how breathless they
are; the assessor is the patient.
Naturally
occurring event
An event that is not dependent on a direct action
taken by a physician, carer, or the patient (i.e.
they occur naturally), and requires interpretation
of whether the event occurred or not by an
assessor.
The person who determines
whether the event occurred or
not.
Myocardial infarction; the assessor is the person
who judges whether the event occurred.
Action-based
event
An event that occurs as a direct result of an
action taken.
The person who made the
decision which led to the
event.
Whether the patient undergoes surgery to
alleviate symptoms during follow-up; the




The occurrence of death from any cause. Not required. Mortality from any cause within 90 days of
randomisation.
Other Any outcome that does not fall into any of the
above deﬁnitions.





An outcome for which two or more of the above
deﬁnitions apply.
Dependent on which of the
above components are
included in the outcome
deﬁnition.
A composite of either death from uncontrolled
bleeding, or requirement for surgery to control
bleeding; the assessors are the person who
determines whether mortality was from
uncontrolled bleeding, and the person who
determined whether the patient required
surgery.
doi:10.1371/journal.pone.0131926.t001
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assessors were blind or not. Furthermore, 18% of trials did not state who performed the
assessment.
We found that lack of blinded assessment was not associated with the outcome type (apart
from action-based outcomes), but did differ according to the assessor. Assessment was blinded
in only 5% of trials using patient assessment, and 24% using physician assessment. In contrast,
assessment was blinded in 71% of trials using an independent assessor.
Despite the fact that using an independent assessor can substantially increase the feasibility
of using blinded assessment, and thus reduce the potential for bias, we found that open trials
were no more likely than double-blinded trials to use independent assessment. This surprising
result has been noted before by Dechartes et al [15], who found that adjudication committees
Table 2. Characteristics of included trials.
Reported as double-
blind (n = 106)
Reported as partially or fully
open-label* (n = 152)
Intervention type—no. (%)
Pharmacological 97 (92) 52 (34)
Other 9 (8) 100 (66)
Participants blinded—no. (%)
Blinded 54 (51) 11 (7)
Unblinded 0 (0) 47 (31)
Not stated 52 (49) 93 (61)
NA 0 (0) 1 (1)
Carers or physicians blinded—no. (%)
Blinded 42 (40) 5 (3)
Unblinded 1 (1) 40 (26)
Not stated 62 (58) 103 (68)
NA 1 (1) 4 (3)
Outcome type—no. (%)
Instrument measured 29 (27) 27 (18)
Rated 18 (17) 25 (16)
By participant 8 17
By other 10 8
Naturally occurring event 30 (28) 28 (18)
Action based event 2 (2) 9 (6)
Decision by participant 1 3
Decision by other 1 6
All-cause mortality 6 (6) 26 (17)
Other 4 (4) 2 (1)
Composite of multiple outcome types 17 (16) 35 (23)






*This includes any trial in which some groups were unblinded, including (but not limited to) patients, those
delivering the intervention, or those in charge of medical care.
doi:10.1371/journal.pone.0131926.t002
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(typically a committee consisting of clinical experts not involved in patient care) were equally
likely to be used in trials of low and high risk of ascertainment bias.
Overall, reporting of various aspects of blinding in open trials was poor. Very few trials
explicitly stated whether patients or carers were blinded. This is similar to what has been found
in previous studies [13, 16], and suggests that guidelines for better reporting have not been as
well adopted as they should be. Given that randomised trials are often used in treatment guide-
lines, it is essential that the methodology of these trials is clearly reported so that others can
adequately judge the relative merits of each trial.
Problematic reporting was not limited to open trials. Amongst self-reported double-blind
trials, only 49% reported whether participants were blinded, 58% whether carers or physicians
are blinded, and 54% whether outcome assessment was blinded. Previous research has found
that some self-reported double-blind trials are actually partially open [13], and we found one
trial which described itself as double-blind but actually had unblinded carers or physicians.
Given the lack of details surrounding blinding in our review, it is possible that a number of
other self-reported double-blind trials were actually open. It is therefore important even for
double-blind trials to carefully describe who was (or was not) blinded.
Only 9 of 109 non-pharmacological trials (8%) used a double-blind design. This is not sur-
prising given the challenges associated with blinding patients and physicians in these scenarios
[17]. However, useful methods of blinding in these circumstances have previously been docu-
mented by Boutron et al [12], and could be more frequently adopted.
It is unclear why so few open trials used blinded outcome assessment. In some circum-
stances, blinded assessment is not feasible, for example patient reported outcomes in trials
when patients are unblinded due to the nature of the intervention. In some cases when blinded
outcome assessment is not possible, it may be possible to modify the outcome definition to
reduce the risk of bias [18]. However, in many cases blinded assessment is possible [11, 12, 19].
Table 3. Assessment of the primary outcome. *
Reported as double-
blind (n = 100)
Reported as partially or fully
open-label** (n = 125)
Who assessed the primary outcome—no. (%)
Participant 11 (11) 22 (18)
Carer or physician 33 (33) 25 (20)
Independently assessed 18 (18) 21 (17)
Not stated 23 (23) 22 (18)
Assessed by multiple groups 15 (15) 35 (28)
Number of assessment groups used for




Was outcome assessment blinded? (all trials)—
no. (%)
Blinded 46 (46) 33 (26)
Unblinded 0 (0) 28 (22)
Not stated 54 (54) 64 (51)
*This table only includes trials which required assessment
**This includes any trial in which some groups were unblinded, including (but not limited to) patients, those
delivering the intervention, or those in charge of medical care.
doi:10.1371/journal.pone.0131926.t003
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For example, in most trials it is possible to have an independent person who is not otherwise
involved in the medical care for a specific patient (and is therefore blinded to their treatment
allocation) to assess their wellbeing. Often, photos or recordings can be taken and sent to an
independent adjudication committee for assessment, and with new technological develop-
ments, this is a particularly promising way of ensuring blinded assessment.
Fig 1. Results for open trials.
doi:10.1371/journal.pone.0131926.g001
Table 4. Blinding of different outcome types in trials reported as partially or fully open-label.
Instrument measured outcomes—no. (%)
Blinded 8/27 (30)
Unblinded 4/27 (15)




Not stated 14/25 (56)
Naturally occurring events—no. (%)
Blinded 9/28 (32)
Unblinded 5/28 (18)




Not stated 2/9 (22)
Multiple outcome types—no. (%)
Blinded 9/35 (26)
Unblinded 8/35 (23)
Not stated 18/35 (51)
doi:10.1371/journal.pone.0131926.t004
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The use of independent assessors may also be helpful in double-blind trials where the integ-
rity of the blind is uncertain. For example, in some double-blind trials, the methods used to
blind participants and investigators may fail, and they may become aware of the treatment allo-
cation. Conversely, patients or physicians may be able to guess their treatment allocation based
on their symptoms or side-effects. It is unclear how often this inadvertent unblinding occurs in
practice, as it is rarely tested or reported [20, 21]. Therefore, more frequent use of independent
assessors could also be considered in double-blind trials where the integrity of the blind is
uncertain.
There are some limitations to our study. The articles we reviewed were written prior to the
release of the 2010 CONSORT statement [22], and reporting may have subsequently improved
since then. Secondly, we included only trials from high impact general medical journals; results
may not be generalizable to lower impact or specialist journals.
Conclusions
Blinded outcome assessment was poorly reported, and was infrequently used. Investigators
should consider using independent assessors more often to increase the feasibility of blinded
assessment.
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Not stated 12/22 (55)
Carer or physician—no. (%)
Blinded 6/25 (24)
Unblinded 7/25 (28)




Not stated 5/21 (24)
Unclear who assessed—no. (%)
Blinded 2/22 (9)
Unblinded 2/22 (9)
Not stated 18/22 (92)
Assessed in multiple ways—no. (%)
Blinded 9/35 (26)
Unblinded 9/35 (26)
Not stated 17/35 (49)
doi:10.1371/journal.pone.0131926.t005
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